Use of real-world evidence for oncology clinical decision making in emerging economies

被引:12
|
作者
Petracci, Fernando [1 ]
Ghai, Chirag [2 ]
Pangilinan, Andrew [2 ]
Suarez, Luis Alberto [3 ]
Uehara, Roberto [4 ]
Ghosn, Marwan [5 ,6 ]
机构
[1] Inst Alexander Fleming, Breast Canc Dept, Ave Cramer 1180, RA-1426 Buenos Aires, Argentina
[2] Real World Evidence Strategy & Solut, IQVIA, New York, NY 10282 USA
[3] Pfizer Inc, B1607EEV, Buenos Aires, DF, Argentina
[4] Pfizer Inc, New York, NY 10017 USA
[5] France Univ Hosp, Hotel Dieu, Hematol & Oncol Dept, Beirut, Lebanon
[6] St Joseph Univ, Beirut, Lebanon
关键词
Asia-Pacific; effectiveness; electronic database; health policy; Latin America; Middle East; randomized clinical trials; real-world data; real-world evidence; safety; RENAL-CELL CARCINOMA; CANCER-PATIENTS; SUNITINIB; PROGRESSION; RESISTANCE; EFFICACY; THERAPY; TRIALS; SAFETY; HEALTH;
D O I
10.2217/fon-2021-0425
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lay abstract Traditionally, randomized clinical trials have been used to provide insights on new medical therapies and continue to remain the gold standard for approval. The-increasing availability of patient level data in the real-world, it is now possible to generate evidence regarding the usage and potential benefits or risks of a medical therapy derived from analysis of real-world data. This evidence is collectively referred to real-world evidence (RWE). randomized clinical trials and RWE are complementary and the area of Oncology especially benefits from RWE to guide clinical decision making across the patient journey. Key benefits include cancer screening and diagnosis, optimal treatment choices (including personalized medicine) and disease management such as dosing and treatment of side effects. In recent times, RWE generation in oncology has been prolific in the USA and western Europe. With expansive biopharmaceutical investments into infrastructure harnessing patient-level data and greater local regulatory guidance, oncology patients in emerging economies may now also have the opportunity to benefit from clinical decision making informed by RWE. Real-world evidence (RWE) can provide insights into patient profiles, disease detection, treatment choice, dosing strategies, treatment sequencing, adverse event management and financial toxicity associated with oncology treatment. However, the full potential of RWE is untapped in emerging economies due to structural and behavioral factors. Structural barriers include lack of regulatory engagement, real-world data availability, quality and integrity. Behavioral barriers include entrenched healthcare professional behaviors that impede rapid RWE understanding and adoption. These barriers can be addressed with close collaboration of healthcare stakeholders; of whom, regulators need to be at the forefront given their ability to facilitate use of RWE in healthcare policy and legislation.
引用
收藏
页码:2951 / 2960
页数:10
相关论文
共 50 条
  • [41] Real-World Decision Making: an Encyclopedia of Behavioral Economics
    Marien, Stacey
    REFERENCE & USER SERVICES QUARTERLY, 2016, 55 (04) : 325 - 326
  • [42] REAL-WORLD EVIDENCE IN MULTIPLE SCLEROSIS (MS): HTA DECISION-MAKING INFLUENCER OR NOT?
    Nanda, S.
    Jindal, S.
    Rohillla, A.
    Mahajan, S.
    Saharia, P.
    VALUE IN HEALTH, 2022, 25 (12) : S344 - S344
  • [43] Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making
    Bakker, Elisabeth
    Plueschke, Kelly
    Jonker, Carla J.
    Kurz, Xavier
    Starokozhko, Viktoriia
    Mol, Peter G. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (01) : 135 - 151
  • [44] Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea
    Lee, Hankil
    Ahn, Hyeon-Soo
    Kwon, Sol
    Kang, Hye-Young
    Han, Euna
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (04):
  • [45] Developing a real-world outcomes forecast model using matched oncology clinical trials and real world evidence to inform policy-making and reimbursement approaches
    Gorman, T.
    Ray, A.
    Brar, S.
    Hinkel, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S961 - S961
  • [46] Insights from Real-World Evidence on the Use of Inhalers in Clinical Practice
    Rubio, Myriam Calle
    Teppa, Pedro Jose Adami
    Hermosa, Juan Luis Rodriguez
    Carro, Miriam Garcia
    Martinez, Jose Carlos Tallon
    Rubio, Consolacion Riesco
    Cortes, Laura Fernandez
    Duenas, Maria Morales
    del Barrio, Valeria Chamorro
    Sanchez-del Hoyo, Rafael
    Aragon, Jorge Garcia
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (04)
  • [47] Artificial intelligence to unlock real-world evidence in clinical oncology: A primer on recent advances
    Bryant, Alex K.
    Zamora-Resendiz, Rafael
    Dai, Xin
    Morrow, Destinee
    Lin, Yuewei
    Jungles, Kassidy M.
    Rae, James M.
    Tate, Akshay
    Pearson, Ashley N.
    Jiang, Ralph
    Fritsche, Lars
    Lawrence, Theodore S.
    Zou, Weiping
    Schipper, Matthew
    Ramnath, Nithya
    Yoo, Shinjae
    Crivelli, Silvia
    Green, Michael D.
    CANCER MEDICINE, 2024, 13 (12):
  • [48] A Review and Comparative Case Study Analysis of Real-World Evidence in European Regulatory and Health Technology Assessment Decision Making for Oncology Medicines
    Zong, Jihong
    Rojubally, Adina
    Pan, Xiaoyun
    Wolf, Birgit
    Greenfeder, Scott
    Upton, Alexander
    Bergeson, Joette Gdovin
    VALUE IN HEALTH, 2025, 28 (01) : 31 - 41
  • [49] Real-World Evidence to Support EU Regulatory Decision Making-Results From a Pilot of Regulatory Use Cases
    Prilla, Stefanie
    Groeneveld, Sophie
    Pacurariu, Alexandra
    Restrepo-Mendez, Maria Clara
    Verpillat, Patrice
    Torre, Carla
    Gartner, Christian
    Mol, Peter G. M.
    Naumann-Winter, Frauke
    Breen, Kieran C.
    Gault, Nathalie
    Gross-Martirosyan, Liana
    Benchetrit, Sylvie
    Aylward, Brian
    Stoyanova-Beninska, Violeta
    O'Donovan, Maura
    Straus, Sabine
    Kjaer, Jesper
    Arlett, Peter
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (05) : 1188 - 1197
  • [50] 'Considering the totality of evidence: Combining real-world data with clinical trial results to better inform decision-making
    Mamtani, Ronac
    Lund, Jennifer
    Hubbard, Rebecca A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 (06) : 814 - 816